August 2012
-
ABC Laboratories, Columbia, MO. The Senior Scientist / Team Leader is a results-oriented, problem-solver and laboratory supervisor who will support ABC Inhalation Product Development programs. Experience with pMDI, DPI and nasal/pulmonary delivery systems is required.… Read more . . .
-
ABC Laboratories, Columbia, MO. The Principal Scientist/Team Leader is a results-oriented, problem-solver and laboratory supervisor who will support ABC Inhalation Product Development programs. Experience with pMDI, DPI and nasal/pulmonary delivery systems is required. Direct hands-on… Read more . . .
-
The British Pharmacopoeia (BP) Inhaled Products Working Party has published its recommendations for BP monographs for inhalation as of September 17, 2012. According to the document, “Safety and efficacy are critical considerations; the Working Party… Read more . . .
-
GlaxoSmithKline says that it submitted a Japanese New Drug Application (JNDA) for its fluticasone furoate (FF)/vilanterol(VI) dry powder inhaler for the treatment of COPD and asthma on September 25, 2012. The FF/VI combination will be… Read more . . .
-
Hovione has announced the addition of services for crystal design, particle size reduction to the micro or nano-scale, and amorphous solid dispersions. The company, which provides particle engineering, formulation development, and clinical manufacture to Phase… Read more . . .
-
The US Patent and Trade Office has awarded Aegis Therapeutics US Patent No. 8,268,791 for “Alkylglycoside compositions for drug administration.” The company is highlighting the patent’s coverage of fast-acting intranasal triptan formulations for the treatment… Read more . . .
-
Lightlake Therapeutics, which is developing naloxone nasal sprays for several eating disorders, has announced the appointment of former FDA Commissioner David Kessler as a strategic advisor. Kessler is the author of The End of Overeating:… Read more . . .
-
Acton Pharmaceuticals has announced plans to launch its Aerospan flunisolide HFA metered dose inhaler in early 2013 after having received FDA approval for the MDI. The product is approved for for the maintenance treatment of… Read more . . .
-
Belgian biopharmaceutical company Ablynx has announced positive results from a Phase 1 of its ALX-0171 inhaled Nanobody for the treatment of respiratory syncytial virus (RSV) infections. According to the company, the study demonstrated the safety… Read more . . .
-
In order to meet rising demand for its GMP nasal spray testing services, Melbourn Scientific has dedicated a laboratory to analysis of droplet size, particle characterization, spray pattern, plume geometry, and device performance testing. The… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland